The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

http://cdmrp.army.mil/funding/kcrp

Consortium Development Award - Letter of Intent due December 20, 2017

• An eligible Principal Investigator (who will be the Consortium Director) will be a faculty member at or above Assistant Professor (or equivalent) level. 
• co-PIs should be at or above Assistant Professor (or equivalent) level.
• Goal of the Consortium Development Award is to ensure the establishment of the consortium infrastructure for future multi-institutional clinical trials
• Provides support to create a Coordinating Center and to establish the necessary collaborations at potential Clinical Trial Sites for the development of a multi-institutional kidney clinical effort
• Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center)
• Awardee will be eligible to apply for FY19 Consortium Award, if funds are available
• Maximum funding of $1.0 million total costs
• Maximum period of performance is 2 years
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Idea Development Award – Letter of Intent due December 20, 2017

Established Investigators: 

• Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
• Early Career Investigators:
• Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Preliminary data is required
• Innovation and Impact are the most important review criteria.
• Clinical Trials are not allowed
• Areas of Emphasis include:
• Microenvironment, Metabolism, Chromatin and Gene Regulation, Rare Cancers, Screening, Early Detection, Novel Imaging Technologies, Liquid Biopsy, Biomarker Development, Prognosis, Targeted Therapies, Immunotherapies, Resistance, Novel Interventions, Surgical, Ablation, Radiation, Prognosis, Managing Toxicity, Survivorship and Patient Experience, Surveillance, Genetic Risk Factors.
• Maximum funding of $400,000 in direct costs (plus indirect costs)
• Period of performance not to exceed 3 years

Concept Award – Letter of Intent due December 20, 2017

• All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.
• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer
• Emphasis on innovation
• Clinical trials not allowed
• Preliminary data not allowed
• Blinded review
• Maximum funding of $75,000 for direct costs (plus indirect costs)
• Maximum period of performance is 1 year

Translational Research Partnership – Letter of Intent due December 20, 2017

• The Initiating PI must be at or above the level of Assistant Professor or equivalent.
• The Partnering PI must be at or above the level of Assistant Professor or equivalent.  Postdoctoral fellows are not eligible to be Partnering PIs

• ·        Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications
• ·        Supports translational correlative studies
• ·        Preliminary data required

• Clinical trials are not allowed
• Maximum funding of $600,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application (letter of intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application (letter of intent) deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org